[1] [1] CHEN Y, YANG Y, CHENG J, et al. Platelet count and mortality of H7N9 infected patients in Guangdong, China［J］. Platelets, 2019, 31(2): 1-4.

[2] [2] TANIKAWA T, UCHIDA Y, TAKEMAE N, et al. Pathogenicity of two novel human-origin H7N9 highly pathogenic avian influenza viruses in chickens and ducks［J］. Archives of Virology, 2019, 164(2): 535-545.

[3] [3] LI Y, WANG Y, SHEN C, et al. Closure of live bird markets leads to the spread of H7N9 influenza in China［J］. PLoS One, 2018, 13(12): e0208884.

[4] [4] SHEN Y, LU H. Global concern regarding the fifth epidemic of human infection with avian influenza A (H7N9) virus in China［J］. Bioscience Trends, 2017, 11(1): 120-121.

[5] [5] JIANG W, HOU G, LI J, et al. Prevalence of H7N9 subtype avian influenza viruses in poultry in China, 2013-2018［J］. Transboundary Emerging Diseases, 2019, 66(4): 1758-1761.

[6] [6] KAGEYAMA T, FUJISAKI S, TAKASHITA E, et al. Genetic analysis of novel avian A(H7N9)influenza viruses isolated from patients in China, February to April 2013［J］. European Communicable Disease Bulletin, 2013, 18(15): 20453.

[7] [7] DONG Xiaochun. Research progress on highly pathogenic H7N9 avian influenza virus ［J］. Tianjin Medical Journal, 2019, 47(8): 874-879.

[8] [8] ZENG X, TIAN G, SHI J, et al. Vaccination of poultry successfully eliminated human infection with H7N9 virus in China［J］. Science China (Life Sciences), 2018, 61(12): 1465-1473.

[9] [9] NACHBAGAUER R, KRAMMER F. Universal influenza virus vaccines and therapeutic antibodies［J］. Clinical Microbiology and Infection, 2017, 23(4): 222-228.

[10] [10] CUN Yina, SONG Shaohui, ZHOU Jian, et al. Passage stability of high yield adaptive strains of influenza B virus cells ［J］. Journal of Virology, 2019, 35(2): 220-224.

[11] [11] GUO Yuanji, CHENG Xiaowen. Influenza virus and its experimental technology ［M］. Beijing:China Three Gorges Press, 1997: 100-106.

[12] [12] REED L, MUENCH H. A simple method of estimating fifty percent endpoints［J］. The American Journal of Hygiene, 1938, 27(3): 493-497.

[13] [13] WU Xueling, FENG Jianping, FAN Jinping, et al. Quality control of a novel cell matrix MDCK cell for influenza vaccine production ［J］. Chinese Journal of Microbiology and Immunology, 2013, 33(12): 943-949.

[14] [14] WU Shaohui, SHU Yuelong. Application prospects of Vero cell influenza vaccine ［J］. Journal of Virology, 2006, 22(1): 70-73.

[15] [15] HE Chunyan, CHEN Ze, WU Shujun, et al. Large-scale culture and purification of Vero cell influenza virus ［J］. Chinese Journal of Biotechnology, 2008, 28(11): 20-24.

[16] [16] YIN Jianwen, JIAO Long, ZHEN Zugang, et al. Preparation of influenza virus vaccine by Vero cells ［J］. Chinese Journal of Biologicals, 2009, 22(10): 48-51.

[17] [17] YE Wenjia, CHEN Yi, DING Yahong, et al. Progress in clinical research of H7N9 influenza vaccine ［J］. Chinese Journal of Laser Biology, 2017, 26(3): 198-204.

[18] [18] QI Y, FAN H, QI X, et al. A novel pyrosequencing assay for the detection of neuraminidase inhibitor resistance-conferring mutations among clinical isolates of avian H7N9 influenza virus［J］. Virus Research, 2014, 179(1): 119-124.

[19] [19] WU Xiaoxue, GOU Xiaoqin, SHI Yu, et al. Meta-analysis of evaluation of immune effect of human H7N9 avian influenza inactivated vaccine ［J］. Preventive Medicine, 2019, 31(3): 54-59.

[20] [20] GUO Qi. Research progress on human H7N9 avian influenza vaccine ［J］. Chinese Journal of Biologicals, 2017, 30(2): 104-108.